Aurobindo recalls mislabeled statin tablets from the U.S. market
A U.S. subsidiary of Aurobindo is pulling statins off the shelf after a mislabeling snafu. (Pixabay)
India-based Aurobindo has been repeatedly knocked by the FDA for its role in global “sartan” recalls for allowing tainted active pharmaceutical ingredients (APIs) into its drugs. Now, a mislabeling snafu is pulling even more of the drugmaker’s generics off U.S. shelves.
An American subsidiary of Aurobindo voluntarily recalled 2,352 bottles—each containing about 1,000 tablets—of generic statins after certain lots were found to have incorrect or missing labels and sometimes missing expiration dates, according to an FDA Enforcement Report.
Aurolife initiated the recall in late July after the product was distributed nationwide, the FDA said. Aurobindo, with 25 manufacturing plants globally, is one of the largest generic drug manufacturers in the world and the second-largest generics producer for the U.S.
Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes
Wednesday, March 24 | 2pm ET / 11am PT
Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.
The most recent recall is unrelated to Aurobindo pulling 80 lots of valsartan off U.S. shelves in February as part of a global FDA recall of “sartan” products linked to potentially carcinogenic APIs produced by Chinese and Indian manufacturers. The recalls from a variety of producers have resulted in shortages in the U.S. of losartan.